Table 1.
Descriptive statistics and group differences.
| Clinical characteristic | Total cohort mean (SD) median (IQR) | Group <=500/yr prednisone (n = 62) PRED- LOW | Group > 500/yr prednisone (n = 52) PRED-HIGH | p-Value |
|---|---|---|---|---|
| Prednisone | 1817.35 (2687.82) | 32.09 (102.67) | 3944.43 (2739.85) | <0.001 |
| Dose (mg in the previous year) | 230 (3311.25) | 0 (0) | 3491 (3168) | |
| Age | 51.82 (15.75) | 52.58 (11.08) | 50.9 (12.23) | 0.45 |
| 52 (11.59) | 53 (13.75) | 52 (18.75) | ||
| Sex (ratio of males) | 52.63% | 54.83% | 50% | 0.74 |
| Race (ratio of African Americans) | 19.29% | 11.29% | 28.85% | 0.03 |
| # organs involved | 2.44 (1.21) | 2 (1.19) | 2.44 (1.19) | 0.051 |
| 2 (2) | 2 (1) | 2 (2) | ||
| % lung involvement | 95.6% | 95.16% | 96.15 | 0.99 |
| Days since first symptom attributed to sarcoidosis | 2820.34 (2652.7) | 3018 (3000.28) | 2585.21 (2172.63) | 0.375 |
| 1652.5 (3099) | 1656 (2656) | 1652 (2620) | ||
| Days since diagnosis of sarcoidosis | 2650.15 (2765.34) | 2900.84 (3200.52) | 2351.25 (2127.63) | 0.27 |
| 1411 (3104.51) | 1410 (3088) | 1426 (2620) | ||
| FVC (% predicted) | 80.86 (19.98) | 85.39 (18.75) | 75.54 (17.99) | 0.005 |
| 83 (23) | 88 (18) | 75 (21.25) | ||
| Stage IV chest radiograph | 14.9% | 19.2% | 11.2% | 0.37 |
| Additional anti-sarcoidosis drugs (% of cohort) | 27.1% | 9.6% | 51.9% | <0.001 |
FVC: forced vital capacity: First rows show means and standard deviations, second rows show median and inter-quartile range (where applicable).